News

Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...
Following the death of two teenage patients with Duchenne muscular dystrophy following Elevidys treatment, Sarepta ...
Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...
Investing.com -- Shares of Sarepta Therapeutics, Inc. (NASDAQ: NASDAQ: SRPT) plummeted 26% following the company’s online statement regarding a patient death associated with its gene therapy ...